- 45.3% of patients receiving OBT = maraviroc 150 mg BID had an undetectable viral load after 24 weeks
- Optimized background therapy alone was enough to suppress viral load <50 copies/mL in 23.0% of patients
The MOTIVATE 1 & 2 trials demonstrated increased activity with more active drugs in OBT 10, 11
In a combined analysis of the MOTIVATE 1 and 2 trials, viremic, treatment-experienced patients with CCR5-tropic HIV-1 were randomized to receive OBT + placebo (n=209) or OBT + maraviroc 150 mg BID (n=426). “Treatment experienced” was defined as resistance to and/or ≥6 months' experience with ≥1 ARV from three classes (≥2 for PIs). Baseline viral load was 4.86 log10 copies/mL for the OBT + placebo group and 4.85 log10 copies/mL for the OBT + maraviroc 150 mg BID group.
Answers to your Questions
Q: What is optimized background therapy (OBT)?
A: Optimized background therapy is the combination of antiretroviral (ARV) drugs most likely to increase CD4 count and decrease viral load based on patient RV history and resistance testing.
Q: Who needs optimized background therapy?
A: The US Department of Health and Human Services recommends optimized background therapy (OBT) for experienced patients1
Adding a new agent with a novel resistance profile or a new mechanism of action in the context of OBT can provide significant ARV activity1
Q: How do I select optimized background therapy?
A: To create the best possible regimen for your patient, you must have all the information possible, including:
- Patient history
- CD4 count
- ARV treatment history
- Viral load
- Past and current resistance tests
Q: Which resistance test provides the most information?
A: PhenoSense GT™ pinpoints a virus's susceptibility to each drug so you can identify all effective treatment options.
Only PhenoSense GT™ combines actual phenotype and genotype information in a single report
For a downloadable version of these answers click here
Click here for more information on PhenoSense GT™ and resistance testing